| MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia AR Pyzer, D Stroopinsky, H Rajabi, A Washington, A Tagde, M Coll, ... Blood, The Journal of the American Society of Hematology 129 (13), 1791-1801, 2017 | 150 | 2017 |
| MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs AR Pyzer, D Stroopinsky, J Rosenblatt, E Anastasiadou, H Rajabi, ... Leukemia 31 (12), 2780-2790, 2017 | 67 | 2017 |
| Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine MR Nahas, D Stroopinsky, J Rosenblatt, L Cole, AR Pyzer, ... British journal of haematology 185 (4), 679-690, 2019 | 57 | 2019 |
| Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma P Ghione, ML Palomba, AR Patel, S Bobillo, K Deighton, CA Jacobson, ... Blood, The Journal of the American Society of Hematology 140 (8), 851-860, 2022 | 41 | 2022 |
| Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease MR Nahas, RJ Soiffer, HT Kim, EP Alyea III, J Arnason, R Joyce, JH Antin, ... Blood, The Journal of the American Society of Hematology 131 (25), 2836-2845, 2018 | 38 | 2018 |
| Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC 1 M Bar‐Natan, D Stroopinsky, K Luptakova, MD Coll, A Apel, H Rajabi, ... British journal of haematology 176 (6), 929-938, 2017 | 30 | 2017 |
| Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial AM Brunner, TM Blonquist, DJ DeAngelo, M McMasters, G Fell, ... The Lancet Haematology 7 (2), e122-e133, 2020 | 26 | 2020 |
| Anti-cancer vaccine therapy for hematologic malignancies: an evolving era MR Nahas, J Rosenblatt, HM Lazarus, D Avigan Blood reviews 32 (4), 312-325, 2018 | 25 | 2018 |
| Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T-cell responses in a murine acute myeloid leukemia model D Stroopinsky, J Liegel, M Bhasin, G Cheloni, B Thomas, S Bhasin, ... Haematologica 106 (5), 1330, 2021 | 20 | 2021 |
| MUC 1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism D Stroopinsky, H Rajabi, M Nahas, J Rosenblatt, M Rahimian, A Pyzer, ... Journal of cellular and molecular medicine 22 (8), 3887-3898, 2018 | 16 | 2018 |
| Decitabine priming enhances mucin 1 inhibition mediated disruption of redox homeostasis in cutaneous T-cell lymphoma S Jain, A Washington, RK Leaf, P Bhargava, RA Clark, TS Kupper, ... Molecular cancer therapeutics 16 (10), 2304-2314, 2017 | 16 | 2017 |
| DCOne as an allogeneic cell-based vaccine for multiple myeloma RK Leaf, D Stroopinsky, AR Pyzer, AM Kruisbeek, S van Wetering, ... Journal of Immunotherapy 40 (9), 315-322, 2017 | 15 | 2017 |
| Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study P Ghione, ML Palomba, H Ghesquieres, S Bobillo, AR Patel, M Nahas, ... Haematologica 108 (3), 822, 2023 | 12 | 2023 |
| ZUMA-19: a phase 1/2 multicenter study of lenzilumab use with Axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with relapsed or refractory large B cell lymphoma (R/R LBCL) SS Kenderian, OO Oluwole, PL McCarthy, R Reshef, P Shiraz, O Ahmed, ... Blood 136, 6-7, 2020 | 10 | 2020 |
| A comparison of clinical outcomes from ZUMA-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed/refractory follicular lymphoma (r/r FL) P Ghione, AR Patel, S Bobillo, K Deighton, C Jacobson, M Nahas Blood 138 (suppl 1), 3543, 2021 | 9 | 2021 |
| Generalized acquired cutis laxa associated with monoclonal gammopathy of dermatological significance SZ Shalhout, MR Nahas, RE Drews, DM Miller Case Reports in Dermatological Medicine 2020, 2020 | 8 | 2020 |
| A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma ML Palomba, P Ghione, AR Patel, M Nahas, S Beygi, AJ Hatswell, ... Expert review of anticancer therapy 23 (2), 199-206, 2023 | 7 | 2023 |
| Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological … M Capelletti, J Liegel, M Themeli, T Mutis, D Stroopinsky, S Orr, D Torres, ... Biology of Blood and Marrow Transplantation 26 (3), S42-S43, 2020 | 7 | 2020 |
| Clinical and immunologic activity of ipilimumab following decitabine priming in post-allogeneic transplant and transplant-naïve patients with relapsed or refractory … JS Garcia, L Werner, BK Tomlinson, M Keng, M Nahas, A Brunner, ... Blood 134, 2015, 2019 | 7 | 2019 |
| ZUMA-19: a phase 1/2 study of axicabtagene ciloleucel plus lenzilumab in patients with relapsed or refractory large B-cell lymphoma OO Oluwole, SS Kenderian, P Shiraz, R Karmali, R Reshef, PL McCarthy, ... Blood 140 (Supplement 1), 10318-10320, 2022 | 6 | 2022 |
